Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in <i>ALK</i>-positive non-small-cell lung cancer

Abstract

<i>ALK</i>-positive tumors progressing on ceritinib is not immunogenic enough to respond to immune checkpoint inhibitors.